Augmentation of creatine in the heart

Mini-Reviews in Medicinal Chemistry

Volumn 16, Issue 1, 2016, Pages 19-28

  Zervou, Sevasti ^a   Whittington, Hannah J ^a   Russell, Angela J ^a,b   Lygate, Craig A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Creatine transporter; Energetics; Heart disease

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CREATINE; CREATINE KINASE; CYCLOCREATINE; GLYCINE AMIDINOTRANSFERASE; GUANIDINOACETATE METHYLTRANSFERASE; GUANIDINOPROPIONIC ACID; TRANSFERASE; CARRIER PROTEIN; CREATINE TRANSPORTER;

AGING; CARDIOTOXICITY; DIET SUPPLEMENTATION; DIFFUSION; DOWN REGULATION; ENZYME ACTIVITY; EXERCISE; HEART; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; HYPOXIA; PASSIVE DIFFUSION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; UPREGULATION; ANIMAL; CARDIAC MUSCLE; DISEASE MODEL; ENZYMOLOGY; GENE EXPRESSION; GENETICS; METABOLISM; MOUSE; PHYSIOLOGY;

ANIMALS; CREATINE; CREATINE KINASE; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HEART; HEART FAILURE; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICE; MYOCARDIUM;

EID: 84955317283     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557515666150722102151     Document Type: Review

References (92)

1. Neubauer S. The failing heart--an engine out of fuel..N Engl. J. Med., 2007, 356(11), 1140-1151.
2. Wyss M.; Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol. Rev., 2000, 80(3), 1107-1213.
3. Snow R.J.; Murphy R.M. Creatine and the creatine transporter: a review. Mol. Cell Biochem., 2001, 224(1-2), 169-181.
4. Ventura-Clapier R.; Garnier A.; Veksler V. Energy metabolism in heart failure. J. Physiol. 2004, 555(Pt 1), 1-13.
5. Wallimann T.; Wyss M.; Brdiczka D.; Nicolay K.; Eppenberger H.M. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem. J., 1992, 281 (Pt 1)21-40.
6. Nascimben L.; Ingwall J.S.; Pauletto P.; Friedrich J.; Gwathmey J.K.; Saks V.; Pessina A.C.; Allen P.D. Creatine kinase system in failing and nonfailing human myocardium. Circulation, 1996, 94(8), 1894-1901.
7. Bessman S.P.; Geiger P.J. Transport of energy in muscle: the phosphorylcreatine shuttle. Science, 1981, 211(4481), 448-452.
8. Ye Y.; Gong G.; Ochiai K.; Liu J.; Zhang J. High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation, 2001, 103(11), 1570-1576.
9. Shen W.; Spindler M.; Higgins M.A.; Jin N.; Gill R.M.; Bloem L.J.; Ryan T.P.; Ingwall J.S. The fall in creatine levels and creatine kinase isozyme changes in the failing heart are reversible: complex post-transcriptional regulation of the components of the CK system. J. Mol. Cell Cardiol., 2005, 39(3), 537-544.
10. Neubauer S.; Frank M.; Hu K.; Remkes H.; Laser A.; Horn M.; Ertl G.; Lohse M.J. Changes of creatine kinase gene expression in rat heart post-myocardial infarction. J. Mol. Cell Cardiol., 1998, 30(4), 803-810.
11. Lygate C.A.; Fischer A.; Sebag-Montefiore L.; Wallis J.; ten Hove M.; Neubauer S. The creatine kinase energy transport system in the failing mouse heart. J. Mol. Cell Cardiol., 2007, 42(6), 1129-1136.
12. Liao R.; Nascimben L.; Friedrich J.; Gwathmey J.K.; Ingwall J.S. Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance. Circ. Res., 1996, 78(5), 893-902.
13. Herrman G.D.; Decherd G.M. The chemical nature of heart failure. Ann. Intl. Med., 1939, 12(8), 1233-1244.
14. Neubauer S.; Remkes H.; Spindler M.; Horn M.; Wiesmann F.; Prestle J.; Walzel B.; Ertl G.; Hasenfuss G.; Wallimann T. Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation, 1999, 100(18), 1847-1850.
15. Neubauer S.; Krahe T.; Schindler R.; Horn M.; Hillenbrand H.; Entzeroth C.; Mader H.; Kromer E.P.; Riegger G.A.; Lackner K.; et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation, 1992, 86(6), 1810-1818.
16. Neubauer S.; Horn M.; Pabst T.; Godde M.; Lubke D.; Jilling B.; Hahn D.; Ertl G. Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur. Heart J., 1995, 16 Suppl O115-118.
17. Neubauer S.; Horn M.; Cramer M.; Harre K.; Newell J.B.; Peters W.; Pabst T.; Ertl G.; Hahn D.; Ingwall J.S.; Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation, 1997, 96(7), 2190-2196.
18. Scheuermann-Freestone M.; Madsen P.L.; Manners D.; Blamire A.M.; Buckingham R.E.; Styles P.; Radda G.K.; Neubauer S.; Clarke K. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation, 2003, 107(24), 3040-3046.
19. Rider O.J.; Francis J.M.; Ali M.K.; Holloway C.; Pegg T.; Robson M.D.; Tyler D.; Byrne J.; Clarke K.; Neubauer S. Effects of catecholamine stress on diastolic function and myocardial energetics in obesity. Circulation, 2012, 125(12), 1511-1519.
20. Lamb H.J.; Beyerbacht H.P.; van der Laarse A.; Stoel B.C.; Doornbos J.; van der Wall E.E.; de Roos A. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation, 1999, 99(17), 2261-2267.
21. Smith C.S.; Bottomley P.A.; Schulman S.P.; Gerstenblith G.; Weiss R.G. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation, 2006, 114(11), 1151-1158.
22. Lygate C.A.; Aksentijevic D.; Dawson D.; ten Hove M.; Phillips D.; de Bono J.P.; Medway D.J.; Sebag-Montefiore L.; Hunyor I.; Channon K.M.; Clarke K.; Zervou S.; Watkins H.; Balaban R.S.; Neubauer S. Living without creatine: unchanged exercise capacity and response to chronic myocardial infarction in creatine-deficient mice. Circ. Res., 2013, 112(6), 945-955.
23. Wallis J.; Lygate C.A.; Fischer A.; ten Hove M.; Schneider J.E.; Sebag-Montefiore L.; Dawson D.; Hulbert K.; Zhang W.; Zhang M.H.; Watkins H.; Clarke K.; Neubauer S. Supranormal myocardial creatine and phosphocreatine concentrations lead to cardiac hypertrophy and heart failure: insights from creatine transporter-overexpressing transgenic mice. Circulation, 2005, 112(20), 3131-3139.
24. Gupta A.; Akki A.; Wang Y.; Leppo M.K.; Chacko V.P.; Foster D.B.; Caceres V.; Shi S.; Kirk J.A.; Su J.; Lai S.; Paolocci N.; Steenbergen C.; Gerstenblith G.; Weiss R.G. Creatine kinasemediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved. J. Clin. Invest., 2012, 122(1), 291-302.
25. ten Hove M.; Lygate C.A.; Fischer A.; Schneider J.E.; Sang A.E.; Hulbert K.; Sebag-Montefiore L.; Watkins H.; Clarke K.; Isbrandt D.; Wallis J.; Neubauer S. Reduced inotropic reserve and increased susceptibility to cardiac ischemia/reperfusion injury in phosphocreatine-deficient guanidinoacetate-N-methyltransferaseknockout mice. Circulation, 2005, 111(19), 2477-2485.
26. Swain S.M.; Whaley F.S.; Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer, 2003, 97(11), 2869-2879.
27. Tokarska-Schlattner M.; Zaugg M.; Zuppinger C.; Wallimann T.; Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J. Mol. Cell Cardiol., 2006, 41(3), 389-405.
28. Sestili P.; Martinelli C.; Colombo E.; Barbieri E.; Potenza L.; Sartini S.; Fimognari C. Creatine as an antioxidant. Amino Acids, 2011, 40(5), 1385-1396.
29. Santacruz L.; Darrabie M.D.; Mantilla J.G.; Mishra R.; Feger B.J.; Jacobs D.O. Creatine Supplementation Reduces Doxorubicin-Induced Cardiomyocellular Injury. Cardiovasc. Toxicol., 2014.
30. Aksentijevic D.; Zervou S.; Faller K.M.; McAndrew D.J.; Schneider J.E.; Neubauer S.; Lygate C.A. Myocardial creatine levels do not influence response to acute oxidative stress in isolated perfused heart. PLoS ONE, 2014, 9(10), e109021.
31. Brosnan J.T.; da Silva R.P.; Brosnan M.E. The metabolic burden of creatine synthesis. Amino Acids, 2011, 40(5), 1325-1331.
32. Baroncelli L.; Alessandri M.G.; Tola J.; Putignano E.; Migliore M.; Amendola E.; Gross C.; Leuzzi V.; Cioni G.; Pizzorusso T. A novel mouse model of creatine transporter deficiency. F1000Res., 2014, 3228.
33. Skelton M.R.; Schaefer T.L.; Graham D.L.; Degrauw T.J.; Clark J.F.; Williams M.T.; Vorhees C.V. Creatine Transporter (CrT; Slc6a8) Knockout Mice as a Model of Human CrT Deficiency. PLoS One, 2011, 6(1), e16187.
34. Cullen M.E.; Yuen A.H.; Felkin L.E.; Smolenski R.T.; Hall J.L.; Grindle S.; Miller L.W.; Birks E.J.; Yacoub M.H.; Barton P.J. Myocardial expression of the arginine:glycine amidinotransferase gene is elevated in heart failure and normalized after recovery: potential implications for local creatine synthesis. Circulation, 2006, 114(1 Suppl), I16-20.
35. Dai W.; Vinnakota S.; Qian X.; Kunze D.L.; Sarkar H.K. Molecular characterization of the human CRT-1 creatine transporter expressed in Xenopus oocytes. Arch. Biochem. Biophys., 1999, 361(1), 75-84.
36. Snow R.J., Murphy, R. M. Creatine and the creatine transporter: a review. Mol. Cell Biochem., 2001, 224(1-2), 169-181.
37. Kristensen AS A.J., Jorgensen TN, Sorensen L, Eriksen J, Loland CJ, Stromgaard K Gether U. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol. Rev., 2011, 63(3), 585-640.
38. Speer O.; Neukomm L.J.; Murphy R.M.; Zanolla E.; Schlattner U.; Henry H.; Snow R.J.; Wallimann T. Creatine transporters: a reappraisal. Mol. Cell Biochem., 2004, 256-257(1-2), 407-424.
39. Boehm E.; Chan S.; Monfared M.; Wallimann T.; Clarke K.; Neubauer S. Creatine transporter activity and content in the rat heart supplemented by and depleted of creatine. Am. J. Physiol. Endocrinol. Metab., 2003, 284(2), E399-406.
40. Cooper R.; Naclerio F.; Allgrove J.; Jimenez A. Creatine supplementation with specific view to exercise/sports performance: an update. J. Int. Soc. Sports Nutr., 2012, 9(1), 33.
41. Persky A.M.; Brazeau G.A. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol. Rev., 2001, 53(2), 161-176.
42. Horn M.; Frantz S.; Remkes H.; Laser A.; Urban B.; Mettenleiter A.; Schnackerz K.; Neubauer S. Effects of chronic dietary creatine feeding on cardiac energy metabolism and on creatine content in heart, skeletal muscle, brain, liver and kidney. J. Mol. Cell Cardiol., 1998, 30(2), 277-284.
43. Ipsiroglu O.S.; Stromberger C.; Ilas J.; Hoger H.; Muhl A.; Stockler-Ipsiroglu S. Changes of tissue creatine concentrations upon oral supplementation of creatine-monohydrate in various animal species. Life Sci., 2001, 69(15), 1805-1815.
44. Osbakken M.; Ito K.; Zhang D.; Ponomarenko I.; Ivanics T.; Jahngen E.G.; Cohn M. Creatine and cyclocreatine effects on ischemic myocardium: 31P nuclear magnetic resonance evaluation of intact heart. Cardiology, 1992, 80(3-4), 184-195.
45. Sharov V.G.; Afonskaya N.I.; Ruda M.Y.; Cherpachenko N.M.; Pozin E.; Markosyan R.A.; Shepeleva, II; Samarenko M.B.; Saks V.A. Protection of ischemic myocardium by exogenous phosphocreatine (neoton): pharmacokinetics of phosphocreatine, reduction of infarct size, stabilization of sarcolemma of ischemic cardiomyocytes, and antithrombotic action. Biochem. Med. Metab. Biol., 1986, 35(1), 101-114.
46. Sharov V.G.; Saks V.A.; Kupriyanov V.V.; Lakomkin V.L.; Kapelko V.I.; Steinschneider A.; Javadov S.A. Protection of ischemic myocardium by exogenous phosphocreatine. I. Morphologic and phosphorus 31-nuclear magnetic resonance studies. J. Thorac. Cardiovasc. Surg., 1987, 94(5), 749-761.
47. Thelin S.; Hultman J.; Ronquist G.; Juhlin C.; Hansson H.E.; Lindgren P.G. Improved myocardial protection by creatine phosphate in cardioplegic solution. An in vivo study in the pig during normothermic ischemia. Thorac. Cardiovasc. Surg., 1987, 35(3), 137-142.
48. Robinson L.A.; Braimbridge M.V.; Hearse D.J. Enhanced myocardial protection with high-energy phosphates in St. Thomas' Hospital cardioplegic solution. Synergism of adenosine triphosphate and creatine phosphate. J. Thorac. Cardiovasc. Surg., 1987, 93(3), 415-427.
49. Cisowski M.; Bochenek A.; Kucewicz E.; Wnuk-Wojnar A.M.; Morawski W.; Skalski J.; Grzybek H. The use of exogenous creatine phosphate for myocardial protection in patients undergoing coronary artery bypass surgery. J. Cardiovasc. Surg (Torino)., 1996, 37(6 Suppl 1), 75-80.
50. Ruda M.; Samarenko M.B.; Afonskaya N.I.; Saks V.A. Reduction of ventricular arrhythmias by phosphocreatine (Neoton) in patients with acute myocardial infarction. Am. Heart J., 1988, 116(2 Pt 1), 393-397.
51. Tokarska-Schlattner M.; Epand R.F.; Meiler F.; Zandomeneghi G.; Neumann D.; Widmer H.R.; Meier B.H.; Epand R.M.; Saks V.; Wallimann T.; Schlattner U. Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membraneprotective effects. PLoS One, 2012; 7(8), e43178.
52. Horn M.; Remkes H.; Dienesch C.; Hu K.; Ertl G.; Neubauer S. Chronic high-dose creatine feeding does not attenuate left ventricular remodeling in rat hearts post-myocardial infarction. Cardiovasc. Res., 1999, 43(1), 117-124.
53. Gordon A.; Hultman E.; Kaijser L.; Kristjansson S.; Rolf C.J.; Nyquist O.; Sylven C. Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc. Res., 1995, 30(3), 413-418.
54. Andrews R.; Greenhaff P.; Curtis S.; Perry A.; Cowley A.J. The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur. Heart J., 1998, 19(4), 617-622.
55. Webster I.; Du Toit E.F.; Huisamen B.; Lochner A. The effect of creatine supplementation on myocardial function, mitochondrial respiration and susceptibility to ischaemia/reperfusion injury in sedentary and exercised rats. Acta Physiol (Oxf)., 2012, 206(1), 6-19.
56. Graef J.L.; Smith A.E.; Kendall K.L.; Fukuda D.H.; Moon J.R.; Beck T.W.; Cramer J.T.; Stout J.R. The effects of four weeks of creatine supplementation and high-intensity interval training on cardiorespiratory fitness: a randomized controlled trial. J. Int. Soc. Sports Nutr., 2009, 618.
57. Murphy A.J.; Watsford M.L.; Coutts A.J.; Richards D.A. Effects of creatine supplementation on aerobic power and cardiovascular structure and function. J. Sci. Med. Sport, 2005, 8(3), 305-313.
58. Ireland Z.; Dickinson H.; Snow R.; Walker D.W. Maternal creatine: does it reach the fetus and improve survival after an acute hypoxic episode in the spiny mouse (Acomys cahirinus)? Am. J. Obstet. Gynecol., 2008, 198(4), 431 e431-436.
59. Bender A.; Beckers J.; Schneider I.; Holter S.M.; Haack T.; Ruthsatz T.; Vogt-Weisenhorn D.M.; Becker L.; Genius J.; Rujescu D.; Irmler M.; Mijalski T.; Mader M.; Quintanilla-Martinez L.; Fuchs H.; Gailus-Durner V.; de Angelis M.H.; Wurst W.; Schmidt J.; Klopstock T. Creatine improves health and survival of mice. Neurobiol. Aging, 2008, 29(9), 1404-1411.
60. Lunardi G.; Parodi A.; Perasso L.; Pohvozcheva A.V.; Scarrone S.; Adriano E.; Florio T.; Gandolfo C.; Cupello A.; Burov S.V.; Balestrino M. The creatine transporter mediates the uptake of creatine by brain tissue, but not the uptake of two creatine-derived compounds. Neuroscience, 2006, 142(4), 991-997.
61. Garbati P.; Adriano E.; Salis A.; Ravera S.; Damonte G.; Millo E.; Balestrino M. Effects of amide creatine derivatives in brain hippocampal slices, and their possible usefulness for curing creatine transporter deficiency. Neurochem. Res., 2014, 39(1), 37-45.
62. Roberts J.J.; Walker J.B. Feeding a creatine analogue delays ATP depletion and onset of rigor in ischemic heart. Am. J. Physiol., 1982, 243(6), H911-916.
63. Jacobstein M.D.; Gerken T.A.; Bhat A.M.; Carlier P.G. Myocardial protection during ischemia by prior feeding with the creatine analog: cyclocreatine. J. Am. Coll. Cardiol., 1989, 14(1), 246-251.
64. Elgebaly S.A.; Allam M.E.; Rossomando E.F.; Cordis G.A.; Forouhar F.; Farghaly A.; Kreutzer D.L. Cyclocreatine inhibits the production of neutrophil chemotactic factors from isolated hearts. Am. J. Pathol., 1990, 137(5), 1233-1241.
65. Houser S.L.; Elkerm A.F.; Wei Z.; Doyle K.; Houser D.; Liu X.K.; Tyles E.; Kaddurah-Daouk R.; Elgebaly S.A. Enhancement of cardiac function by cyclocreatine in models of cardiopulmonary bypass. J. Mol. Cell Cardiol., 1995, 27(4), 1065-1073.
66. Oudman I.; Clark J.F.; Brewster L.M. The effect of the creatine analogue beta-guanidinopropionic acid on energy metabolism: a systematic review. PLoS One, 2013, 8(1), e52879.
67. Phillips D.; Ten Hove M.; Schneider J.E.; Wu C.O.; Sebag-Montefiore L.; Aponte A.M.; Lygate C.A.; Wallis J.; Clarke K.; Watkins H.; Balaban R.S.; Neubauer S. Mice over-expressing the myocardial creatine transporter develop progressive heart failure and show decreased glycolytic capacity. J. Mol. Cell Cardiol., 2010, 48(4), 582-590.
68. Santacruz L.; Hernandez A.; Nienaber J.; Mishra R.; Pinilla M.; Burchette J.; Mao L.; Rockman H.A.; Jacobs D.O. Normal cardiac function in mice with supraphysiological cardiac creatine levels. Am. J. Physiol. Heart Circ. Physiol., 2014, 306(3), H373-H381.
69. Lygate C.A.; Bohl S.; ten Hove M.; Faller K.M.; Ostrowski P.J.; Zervou S.; Medway D.J.; Aksentijevic D.; Sebag-Montefiore L.; Wallis J.; Clarke K.; Watkins H.; Schneider J.E.; Neubauer S. Moderate elevation of intracellular creatine by targeting the creatine transporter protects mice from acute myocardial infarction. Cardiovasc. Res., 2012, 96(3), 466-475.
70. Wu F.; Zhang J.; Beard D.A. Experimentally observed phenomena on cardiac energetics in heart failure emerge from simulations of cardiac metabolism. Proc. Natl. Acad. Sci. USA, 2009, 106(17), 7143-7148.
71. Guerrero-Ontiveros M.L.; Wallimann T. Creatine supplementation in health and disease. Effects of chronic creatine ingestion in vivo: down-regulation of the expression of creatine transporter isoforms in skeletal muscle. Mol. Cell Biochem., 1998, 184(1-2), 427-437.
72. Ten Hove M.; Makinen K.; Sebag-Montefiore L.; Hunyor I.; Fischer A.; Wallis J.; Isbrandt D.; Lygate C.; Neubauer S. Creatine uptake in mouse hearts with genetically altered creatine levels. J. Mol. Cell Cardiol., 2008, 45(3), 453-459.
73. Loike J.D.; Zalutsky D.L.; Kaback E.; Miranda A.F.; Silverstein S.C. Extracellular creatine regulates creatine transport in rat and human muscle cells., Proc. Nat. Acad. Sci. USA 1988, 85(3), 807-811.
74. Zervou S.; Ray T.; Sahgal N.; Sebag-Montefiore L.; Cross R.; Medway D.J.; Ostrowski P.J.; Neubauer S.; Lygate C.A. A role for thioredoxin-interacting protein (Txnip) in cellular creatine homeostasis. Am. J. Physiol. Endocrinol. Metab., 2013, 305(2), E263-270.
75. Darrabie M.D.; Arciniegas A.J.; Mantilla J.G.; Mishra R.; Vera M.P.; Santacruz L.; Jacobs D.O. Exposing cardiomyocytes to subclinical concentrations of doxorubicin rapidly reduces their creatine transport. Am. J. Physiol. Heart Circ. Physiol., 2012, 303(5), H539-548.
76. Shojaiefard M.; Christie D.L.; Lang F. Stimulation of the creatine transporter SLC6A8 by the protein kinase mTOR. Biochem. Biophys. Res. Commun., 2006, 341(4), 945-949.
77. Strutz-Seebohm N.; Shojaiefard M.; Christie D.; Tavare J.; Seebohm G.; Lang F. PIKfyve in the SGK1 mediated regulation of the creatine transporter SLC6A8. Cell Physiol. Biochem., 2007, 20(6), 729-734.
78. Almilaji A.; Sopjani M.; Elvira B.; Borras J.; Dermaku-Sopjani M.; Munoz C.; Warsi J.; Lang U.E.; Lang F. Upregulation of the Creatine Transporter Slc6A8 by Klotho. Kidney Blood Press. Res., 2014, 39(6), 516-525.
79. Fezai M.; Elvira B.; Borras J.; Ben-Attia M.; Hoseinzadeh Z.; Lang F. Negative Regulation of the Creatine Transporter SLC6A8 by SPAK and OSR1. Kidney Blood Press. Res., 2014, 39(6), 546-554.
80. Brown E.L.; Snow R.J.; Wright C.R.; Cho Y.; Wallace M.A.; Kralli A.; Russell A.P. PGC-1alpha and PGC-1beta increase CrT expression and creatine uptake in myotubes via ERRalpha. Biochim. Biophys. Acta, 2014, 1843(12), 2937-2943.
81. Ndika J.D.; Martinez-Munoz C.; Anand N.; van Dooren S.J.; Kanhai W.; Smith D.E.; Jakobs C.; Salomons G.S. Posttranscriptional regulation of the creatine transporter gene: functional relevance of alternative splicing. Biochim. Biophys. Acta, 2014, 1840(6), 2070-2079.
82. Omerovic E.; Bollano E.; Lorentzon M.; Walser M.; Mattsson-Hulten L.; Isgaard J. Growth hormone induces myocardial expression of creatine transporter and decreases plasma levels of IL-1beta in rats during early postinfarct cardiac remodeling. Growth Horm IGF Res., 2003, 13(5), 239-245.
83. Darrabie M.D.; Arciniegas A.J.; Mishra R.; Bowles D.E.; Jacobs D.O.; Santacruz L. AMPK and substrate availability regulate creatine transport in cultured cardiomyocytes. Am. J. Physiol. Endocrinol. Metab., 2011, 300(5), E870-876.
84. Li H.; Thali R.F.; Smolak C.; Gong F.; Alzamora R.; Wallimann T.; Scholz R.; Pastor-Soler N.M.; Neumann D.; Hallows K.R. Regulation of the creatine transporter by AMP-activated protein kinase in kidney epithelial cells. Am. J. Physiol. Renal. Physiol., 2010, 299(1), F167-177.
85. Straumann N.; Wind A.; Leuenberger T.; Wallimann T. Effects of N-linked glycosylation on the creatine transporter. Biochem. J., 2006, 393(Pt 2), 459-469.
86. Wang W.; Jobst M.A.; Bell B.; Zhao C.R.; Shang L.H.; Jacobs D.O. Cr supplementation decreases tyrosine phosphorylation of the CreaT in skeletal muscle during sepsis. Am. J. Physiol. Endocrinol. Metab., 2002, 282(5), E1046-1054.
87. Zhao C.R.; Shang L.; Wang W.; Jacobs D.O. Myocellular creatine and creatine transporter serine phosphorylation after starvation. J. Surg. Res., 2002, 105(1), 10-16.
88. Walzel B.; Speer O.; Boehm E.; Kristiansen S.; Chan S.; Clarke K.; Magyar J.P.; Richter E.A.; Wallimann T. New creatine transporter assay and identification of distinct creatine transporter isoforms in muscle. Am. J. Physiol. Endocrinol. Metab., 2002, 283(2), E390-401.
89. Gianella-Borradori M.; Christou I.; Bataille C.J.; Cross R.L.; Wynne G.M.; Greaves D.R.; Russell A.J. Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists. Bioorg. Med. Chem., 2015, 23(1), 241-263.
90. Stahura F.L.; Bajorath J. New methodologies for ligand-based virtual screening. Curr. Pharm. Des., 2005, 11(9), 1189-1202.
91. Freedman J.C.; Novak T.S. Optical measurement of membrane potential in cells, organelles, and vesicles. Met. Enzymol., 1989, 172, 102-122.
92. Ndika J.D.; Lusink V.; Beaubrun C.; Kanhai W.; Martinez-Munoz C.; Jakobs C.; Salomons G.S. Cloning and characterization of the promoter regions from the parent and paralogous creatine transporter genes. Gene, 2014, 533(2), 488-493.